Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
  • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
  • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07F9/653—Five-membered rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
  • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates to novel derivatives of oxazolidinone, preparation methods of the same, and pharmaceutical compositions comprising the same for use in an antibiotic.
• oxazolidinone compounds are not products of fermentation, but artificially synthesized ones, and various structures of their derivatives are known.
• 3-phenyl-2-oxazolidinone derivatives having one or two substituents are stated in U.S. Pat. Nos. 4,948,801, 4,461,773, 4,340,606, 4,476,136, 4,250,318 and 4,128,654.
• 3-[(Monosubstituted) phenyl]-2-oxazolidinone derivatives of Formula 2 are disclosed in EP 0312000, J. Med. Chem. 32, 1673(1989), J. Med. Chem. 33, 2569 (1990), Tetrahedron, 45, 123(1989)., etc.
• oxazolidinone derivatives of Formulas 3 and 4 (WO 93/23384, WO 95/14684 and WO 95/07271). Having succeeded in gaining the approval of the Food and Drug Administration (FDA) of U.S.A., the oxazolidinone derivative of Formula 3, by the name of 'Zyvox', has came into the market.
• FDA Food and Drug Administration
• these conventional synthetic oxazolidinone compounds were found to suffer from the disadvantage of showing antibacterial activity against a narrow spectrum of bacteria, being toxic to humans, and being poor in therapeutic activity in vivo.
• Zyvox may be used restrictively as injection since the solubility of Zyvox against water is inadequate for use in injection, which is about 3mg/ml.
• WO 93/09103 discloses derivatives of phenyl oxazolidinone, substituted with heterocyclics such as thiazole, indole, oxazole and quinole, as well as pyridine, at position 4 of the phenyl ring.
• heterocyclics such as thiazole, indole, oxazole and quinole, as well as pyridine
• these derivatives of oxazolidinone are known as providing insufficient medicinal effects because the heterocyclics bear simple substituents such as alkyl or amino groups.
• synthesizing derivatives of phenyl oxazolidinone, having with pyridine or derivatives of phenyl at position 4 of the phenyl ring was described.
• the compounds synthesized are potent in inhibitory activity against a broad spectrum of bacteria and are also superior antibiotic to Zyvox. However, the compounds are unable to be formulated as injection because solubility of the same is under 30/ €/ ⁇ rtf. Accordingly, the intensive and thorough research on oxazolidinone derivatives, conducted by the present inventors aiming to overcome the above problems encountered in prior arts, resulted in the finding oxazolidinone derivatives as well as prodrugs thereof, wherein the prodrugs are prepared by reacting amino acid or phosphate with the oxazolidinone derivatives having hydroxyl group.
• salts of the oxazolidinone derivatives prodruged were easily synthesized by using amine group of amino acid of the same to synthesize organic acid or inorganic acid and by using a hydroxyl group of phosphate and one selected from sodium and calcium.
• the oxazolidinone derivatives have excellent effects on antibiotic activity and the solubility of the same is greatly enhanced. Disclosure of the Invention Technical problem It is an object of the present invention to provide novel derivatives of oxazolidinone. It is another object of the present invention to provide a method of preparing the above-mentioned derivatives. It is still another object of the present invention to provide a pharmaceutical composition comprising the above-mentioned derivatives for use in an antibiotic.
• the present invention provides novel derivatives of oxazolidinone corresponding to Formula 1 defined below.
• X represents carbon or nitrogen.
• Ri and Ri' respectively represent hydrogen or fluorine.
• R 2 represents -NR 5 R( 5 , -OR 7 , triazol, fluorine, alkylphosphate, monophosphate or a metal salt of phosphate;
• R 5 and R 6 ⁇ which are the same or different, respectively represent hydrogen, C. sub. 1-4 alkyl group or acetyl;
• R 7 is hydrogen, C. sub. 1-3 alkyl group or acylated amino acid.
• amino acid refers to alanine, glycine, proline, isoleucine, leucine, phenylalanine, /3-alanine or valine.
• Het which is a heterocyclic ring or a hetero aromatic ring, refers to pyrrole, furan, piperazine, piperidine, imidazole, 1,2,4-triazol, 1,2,3-triazol, tetrazole, pyrazole, pyrrolidine, oxazole, isoxazole, oxadiazole, pyridin, pyrimidine, thiazole or pyrazine.
• R 3 and R 4 which are the same or different, respectively refer to hydrogen, C. sub. 1- 4 alkyl group that is substituted or unsubstituted with cyano, -(CH 2 )m-OR 7 (m represents 0, 1, 2, 3, 4) or ketone.
• the derivatives of oxazolidinone corresponding to Formula 1 may be used for a pharmaceutically acceptable salt, it is preferably an acid addition salt prepared by using pharmaceutically acceptable free acid.
• the free acid may be inorganic or organic.
• the inorganic free acid may comprise hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc.
• the organic free acid may include citric acid, acetic acid, lactic acid, maleic acid, fumaric acid, gluconic acid, methane sulfonic acid, glyconic acid, succinic acid, 4-toluenesulfonic acid, trifluoroacetic acid, galuturonic acid, embonic acid, glutamic acid, aspartic acid, etc.
• Preferred compounds of the oxazolidinone derivatives according to the present invention include the following compounds and their structures are described in Table 1. 1) (S)-3-(4-(2-(2-oxo-4-glycyloxymethylpylolidin- 1 -yl) ⁇ yridin-5-yl)-3- fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid, 2) (S)-3-(4-(2-(4-glycyloxymethyl-l 5 2,3-triazol-l-yl) ⁇ yridin-5-yl)-3-fluoro ⁇ henyl)- 2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid, 3) (S)-3-(4-(2-(5-glycyloxymethylisoxazol-3-yl)pyridin-5-yl)-3-fluorophenyl)-2- oxo-5-ox
• 'Ac' represents acetyl and 'TfOH' refers to trifluoroacetic acid.
• Z represents C. sub. 1 ⁇ 4 alkyl group, X, R Ri ', R 2 ,
• R 3 and are as defined in Formula 1 and Y represents halogen.
• the method of preparing the derivatives of oxazolidinone according to the present invention comprises; substituting a halogen atom for a hydrogen atom on phenyl of a derivative( 11 ) of hydroxymethyloxazolidinone thereby to form a derivative( III )(Step 1); substituting stannyl for a halogen atom(Y) of the derivative( lll ) to form a derivative( IV)(Step 2); reacting the derivative(IV) with pyridine or phenyl derivative that is substituted to bromine or iodine to form a derivative( V ) of oxazolidinone having pyridine ring or phenyl ring(Step 3); and reacting the derivative( V ) with amino acid having a protecting group and then with acid thereby to eliminate the protecting group and to form salts of the compounds corresponding to Formula 1, or subjecting the derivative( V ) to react with phosphate and then with metallic salt thereby to form salts of the compounds corresponding
• the derivative( 11 ) of hydroxymethyloxazolidinone may be synthesized by conventional methods.
• a method may comprise substituting an amino group of anilin for a benzyloxycarbonyl group and reacting a substituted compound with glycidylbutylate in a state of strong bases thereby to form the derivative( 11 ).
• the state may be prepared by adding a strong base; preferably the strong base may include 77-butyllitium, sec-butyllitium, tert- butyllitium, etc., more preferably tt-butyllitium. Further, it is preferable to subject the method at a temperature of about -78 °C in liquid nitrogen.
• the Step 1 is subjected to substitute a hydrogen atom of phenyl group of the derivative( I I ) for a halogen atom, preferably for an iodine atom.
• the substituted reaction may be subjected preferably by adding iodine monochloride(ICI) or trifluoroacetic acid silver salt(CF 3 COOAg) and adding iodine at room temperature.
• the Step 2 is subjected the derivative( lll) to react with hexamethylditin, hexabutylditin or tributyltin hydride by adding a catalyst of palladium to form the derivative(IV) of which iodine atom is substituted for a trimethylstannyl group or a tributylstannyl group.
• the catalyst of palladium may comprise dichlorobistriphenylphosphine palladium( 11 ), tetrakistriphenylphosphine palladium(O), etc.
• Step 2 It is preferred to carry out the Step 2 in a solvent of 1,4-dioxan, dimethylformamide, tetrahydrofuran, l-methyl-2-pyrolidone, etc. at a temperature of about 90 to 150 °C .
• the Step 3 is carried out by reacting the derivative(IV) with a compound having hetero ring on phenyl or pyridine ring thereby to form the derivative( V ).
• a catalyst of palladium added in the Step 3 may be identical to that of palladium in Step 2. It is preferred to carry out the Step 3 in a solvent of dimethylformamide, 1- methyl-2-pyrolidone, etc. at a temperature of about 100 tol20 °C .
• the Step 4 is performed by reacting the derivative( V ) with amino acid that is protecting an amino group with t-butyloxycarbonyl, dicyclohexylcarbodiimide and 4-dimethylaminopyridme thereby to form the derivative( I ) having amino group.
• the amino acid may include alanine, glycine, proline, isoleucine, leucine, phenylalanine, ⁇ - alanine, valine, etc.
• a solvent comprises dimethylformamide, 1- methyl-2-pyrolidone, etc.
• a reaction by adding the derivative( V ) with amino acid is carried out by stirring for about.5 hours above at room temperature.
• a mixture of the derivative( V ) and amino acid reacts to a strong acid such as trifluoroacetic acid, etc. to eliminate a protecting group.
• the solvent is removed from the mixture and the mixture is crystallized thereby to provide a salt of the derivative of oxazolidinone corresponding to Formula 1.
• a reaction by adding the derivative( V ) with amino acid is carried out by stirring for about 2 hours above at room temperature.
• the salt of the derivative of formula 1, prepared by using amino acid at position R 3 or R 4 in a method known similarly to the above method, may be gained.
• a phosphate metallic salt of the derivative( I ) may be formed by adding sodiummethoxide, sodium hydroxide, etc. to a composition in a solvent such as methanol, ethanol etc., the composition is prepared by dissolving the derivative( V ) in trimethylphosphate or triethylphosphate, adding phosphorous oxy chloride and stirring for about 12 hours at room temperature.
• the phosphate metallic salt may be produced by reacting the derivative( V ) with tetrazole and derivates of amidite at room temperature, oxidizing a reacted compound, synthesizing a derivative of alkylphosphate, eliminating alkyl group using a strong acid thereby to form a derivative of phosphate acid, and converting the derivative of phosphate acid into the phosphate metallic salt by the above-mentioned method.
• the present invention provides a pharmaceutical composition comprising the derivatives of oxazolidinone corresponding to Formula 1 for use in an antibiotic.
• the oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria, against methicillin resistant Staphylococcus aureus(MRSA) and vancomycin resistant Enterococci(VRE) and have excellent relatively antibiotic activity with a relatively low concentration thereof or in vivo.
• the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram- positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium.
• Gram- positive bacteria such as Staphylococi, Enterococci and Streptococi
• anaerobic microorganisms such as Bacteroides and Clostridia
• acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium.
• the prodrugs have superior solubility to compounds that are not formed as prodrugs: the solubility of the prodrugs represents above 28mg/nrv ⁇ and the solubility of the compound 10mg/m ompound 10).
• the prodrugs stabilize in water or acidic solution and change to hydroxylmethyl compounds by being reverted using esterase and phosphatase in a blood thereby to develop easy formulation for injection or oral administration.
• the composition of the present invention may comprise at least one effective ingredient having functions similar to those of the derivatives of oxazolidinone.
• at least one specie of the compound of formula 1 may be admixed with at least one pharmaceutically acceptable carrier.
• the pharmaceutical acceptable carrier may include saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, malto- dextrin solution, glycerol, ethanol, etc.
• the pharmaceutical composition may contain conventional expedient such as antioxidizing agent, buffer, soil cleaner, etc.
• the compositions are admixed with diluents, disintegrants, surface active agents, binders, lubricants, aqueous solution, suspension, etc. to be formed for injection, powders, capsules, granules, tablet, etc.
• the formulation is prepared using proper methods described in Remington's Pharmaceutical Science(the newest edition), Mack Publishing Company, Easton PA, etc.
• the compound of the present invention may be administrated orally or parenterally, such as intravenously, hypodermically, intra-abdominally, topically, etc.
• the dosage of the compound may vary depending upon the particular compound utilized, the mode of administration, the condition, and severity thereof, of the condition being treated, as well as the various physical factors related to the individual being treated.
• satisfactory results may be obtained when the compounds of the present invention are administered to the individual in need at a daily dosage of about 10 mg to about 25 mg per kilogram of body weight, preferably about 13 mg to about 20 mg per kilogram of body weight, more preferably administered each of divided doses to many times per day.
• the Lethal Dose (LD 50 ) of the oxazolidinone derivatives shows above lg/kg in test of acute toxicity so that the derivatives are found stable.
• the oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity.
• the prodrugs prepared by reacting the compound having hydroxyl with amino acid or phosphate, have high solubility thereof against water.
• the derivatives of the present invention may . exert potent antibacterial activity versus various human and animal pathogens, including Gram- positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the derivatives of oxazolidinone are used in an antibiotic.
• Preparation example 1 Preparation of N-Carbobenzyloxy-3-fluoroaniline 3-fluoroaniline lOOg was dissolved in 1L of tetrahydrofuran(THF) and the solution was added with 150g(1.8 mol) of sodium bicarbonate(NaHC0 3 ). After being cooled to 0°C , the solution was slowly added with 154ml of N- carbobenzyloxy chloride(CbzCl) for reaction. While the temperature was maintained at 0 °C , the reaction mixture was let to react for 2 hours with stirring. Afterwards, the reaction was extracted with 0.5L of ethyl acetate.
• Preparation example 2 Preparation of (RV3-(3-fluorophenyl)-2-oxo-5- oxazolidinylmethanol 132g of N-carbobenzyloxy-3-fluoroaniline 132g prepared in the Preparation example 1 was dissolved in 1.3L of tetrahydrofuran and the solution was cooled to - 78 °C . 370ml of 7 ⁇ -buthyllitium(n-BuLi, 1.6M /n-hexane) was slowly added to the solution in a nitrogen atmosphere, followed by stirring for 10 min.
• Preparation example 4 Preparation of (R)-3-(4-tributhyIstannyl-3- fluorophenyl)-2-oxo-5-oxazolidinylmethanol
• 52g of hexabutylditin((Bu 3 Sn) 2 ) and 9.3g of dichlorobistriphenylphosphinpalladium were added into the solution, and stirred for 2 hours.
• the solution was filtered using celite and concentrated in vacuo.
• Preparation example 6 Preparation of 2-(tetrazol-5-yl)-5-bromopyridine lOg of 2-cyano-5-bromopyridine prepared in the Preparation example 5 was dissolved in 100ml of dimethylformamide, 5.33g of sodiumazide, and 4.4g of ammoniumchloride were added to the solution at room temperature, and the solution was stirred at the temperature of 110 ° C for 3 hours for reaction. The reaction mixture was added with water and then was extracted with ethyl acetate. The organic layer, thus separated, was washed with brine, dehydrated, filtrated and concentrated in vacuo thereby to obtain 10.5g of the title compound. Yield 85%.
• Preparation example 7 Preparation of 2-(l-methyltetrazol-5-yD-5- bromopyridine and 2-(2-methyltetrazol-5-yl)-5-bromopyridine 10.5g of 2-(tetrazol-5-yl)-5-bromopyridine prepared in the Preparation example 6 was dissolved in 100ml of dimethylformamide. And then 6.5g of sodiumhydroxide was added to the solution and 9.3g of iodomethane was slowly added to the solution at the temperature of 0 °C . The solution was stirred for 6 hours at room temperature, added with water, extracted with ethyl acetate.
• Preparation example 8 Preparation of 2-(2-methyl-[l,3,41oxadiazol-5-yl)-5- bromopyridine In 130ml of acetic anhydride was dissolved 8.6g of 2-(tetrazol-5-yl)-5- bromopyridine prepared in the Preparation example 6. And then the solution was added with 15ml of pyridine and stirred for 3 hours for reaction. The reaction mixture was added with ethyl acetate and extracted to separate organic layer. And then the organic layer was washed with water and brine. The organic layer was dehydrated, filtrated and concentrated in vacuo to give 7.3 g of the title compound. Yield 80%.
• Example 1 Preparation of (RV3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-hydroxymethyl oxazolidin ⁇ 2-on (compound 10)
• compound 10 In 150ml of l-methyl-2-pyrrolidone was dissolved 37g of (R)-3-(4- tributhylstannyl-3-fluorophenyl)-2-oxo-5-oxazolidinylmethanol.
• Example 2 Preparation of (R)-3-(4-(2-(2-methyl-[l,3,41oxadiazol-5-yl)pyridin- 5-yl)-3-fluorophenylV5-hydroxymethyl oxazolidin-2-on (compound 16)
• the title compound 6.6g(yield 30%) was prepared in a method similar to that of Example 1, except that, 14.3g of 2-(2-methyl-[l,3,4]oxadiazol-5-yl)-5- bromopyridine, instead of 2-(2-methyltetrazol-5-yl)-5-bromo ⁇ yridine, was used as a starting material.
• Example 3 Preparation of (R)-3-(4-(2- ⁇ i,2,41triazol-l-yI)pyridin-5-yl)-3- fluorophenyD-5-hydroxymethyl oxazolidin-2-on (compound 17)
• the same procedure as in Example 1 was conducted, except for using, instead of 2-(2-methyltetrazol-5-yl)-5-bromopyridine, 200mg of 2-([l,2,4]triazol-l- yl)-5-bromopyridine as a starting material, to prepare the title compound 150mg(yield 48%).
• Example 4 Preparation of (R)-3-(4-(4-(4,5-dimethyloxzoI-2-yl phenyl)-3- fluorophenyl -5-hydroxymethyl oxazolidin-2-on (compound 21)
• the same procedure as in Example 1 was conducted, except for using, instead of 2-(2-methyltetrazol-5-yl)-5-bromo ⁇ yridine, lg of 4-(4,5-dimethyloxazol- 2-yl)bromobenzene as a starting material, to prepare the title compound 780mg(yield 76%).
• Example 5 Preparation of (RV3-(4-(2-([l,2,31triazol-l-vnpyridin-5-yl -3- fluorophenyl)-5-hydroxymethyloxazolidin-2-on (compound 24)
• the same procedure as in Example 1 was conducted, except for using, instead of 2-(2-methyltetrazol-5-yl)-5-bromopyridine, 2g of 2-([ 1,2,3 ]triazol-l-yl)-5- bromopyridine as a starting material, to prepare the title compound 1.2g.
• Example 6 Preparation of )-3-(4-(2-(fl,2,31triazol-2-ynpyridin-5-yI)-3- fluorophenyl -5-hydroxymethyl oxazolidin-2-on (compound 29)
• the same procedure as in Example 1 was conducted, except for using, instead of 2-(2-methyltetrazol-5-yl)-5-bromopyridine, lg of 2-([l,2,3]triazol-2-yl)-5- bromopyridine as a starting material, to prepare the title compound 0.7g.
• 1H NMR(DMSO-d 6 ) ⁇ 8.74(s,lH), 8.25(dd,lH), 8.23(s,lH), 8.11(d,lH),
• Example 7 Preparation of (R)-3-(4-(4-(4-cyanomethyl thiazol-2-yl)phenyl)-3- fluorophenyI)-5-hydroxymethyl oxazolidin-2-on (compound 32)
• the same procedure as in Example 1 was conducted, except for using, instead of 2-(2-methyltetrazol-5-yl)-5-bromopyridine, lg of 4-(4-cyanomethyl thiazol-2-yl)bromobenzene as a starting material, to prepare the title compound 520mg.
• 1H NMR(DMSO-d 6 ) ⁇ 8.04(s,lH), 8.00(s,lH), 7.65(m,5H), 7.47(dd,lH),
• Example 8 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3,5- difluorophenyl)-5-hydroxymethyl oxazolidin-2-on (compound 38)
• the same procedure as in Example 1 was conducted, except for using, instead of (R)-3-(4-tributhylstannyl-3-fluorophenyl)-2-oxo-5-oxazolidinylmethanol, (R)-3-(4-tributhylstannyl-3,4-difluorophenyl)-2-oxo-5-oxazolidinylmethanol as a starting material, to prepare the title compound.
• Example 9 Preparation of (R)-3-(4-(2-(2-methyl-fl,3,4]oxadiazol-5-yl)pyridin- 5-yl)-3,4-difluorophenyQ-5-hydroxymethyl oxazolidin-2-on (compound 39)
• the same procedure as in Example 1 was conducted by using (R)-3-(4- tributhylstannyl-3, 4-difluorophenyl)-2-oxo-5-oxazolidinylmethanol and 2-(2- methyl-[l,3,4]oxadiazol-5-yl)-5-bromopyridine as a starting material, to prepare the title compound.
• Example 11 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-on trifluoroacetic acid (compound 20)
• the title compound was prepared in a method similar to that of Example 10 using BOC-valline, instead of BOC-glycine.
• Example 12 Preparation of (R)-3-(4-(2-n,2,31triazol-l-yl pyridin-5-yl)-3- fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid (compound 22)
• the title compound was prepared in a method similar to that of Example 10 using compound 24.
• Example 13 Preparation of (R)-3-(4-(4-(4,5-din ⁇ ethyloxazol-2-yl)phenyl)-3- fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid (compound 23)
• the title compound was prepared in a method similar to that of Example 10 using compound 21.
• 1H NMR(DMSO-d 6 ) ⁇ 8.31(s,3H), 7.97(d,2H), 7.64(m,4H), 7.45(dd,lH), 5.01(m,lH), 4.47(m,2H), 4.25(t,lH), 3.94(dd,lH), 3.90(s,2H)
• Example 14 Preparation of (R)-3-(4-(2-(2-methyl-fl,3,41oxadiazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid (compound 27)
• the title compound was prepared in a method similar to that of Example 10 using compound 16.
• Example 15 Preparation of (R)-3-(4-(4-(4-(4-cyanomethyl thiazol-2-yl)phenyI)-3- fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid (compound 34)
• the title compound was prepared in a method similar to that of Example 10 using compound 32.
• 1H NMR(DMSO-d 6 ) ⁇ 8.25(s,3H), 8.03(d,2H), 7.68(m,5H), 7.44(dd,lH), 5.01(m,lH), 4.48(m,2H), 4.25(m,3H), 3.92(m,3H)
• Example 16 Preparation of (R)-3-(4-(2-(fl,2,31triazol ⁇ 2-yl)pyridin-5-yl)-3- fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid (compound 35)
• the title compound was prepared in a method similar to that of Example 10 using compound 29.
• Example 17 Preparation of (S)-3-(4-(2-(2-oxo-4-glycyloxymethylpyrrolidm-l- yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid (compound 1) 1.
• Example 18 Preparation of (S)-3-(4-(2-(4-glvcyloxymethyHl.,2,31triazol-l- yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid (compound 2)
• the same procedure as in Example 17 was conducted, except for using, instead of 2-(2-oxo-4-hydroxymethylpyrrolidin-l-yl)-5-bromopyridine, 2-(4- hydroxymethyl-[l,2,3]triazol-l-yl)-5-bromopyridine as a starting material, to prepare the title compound.
• 1H NMR(DMSO-d 6 ) ⁇ 8.96(s,lH), 8.89(s,lH), 8.22(m,6H), 7.74(t,lH),
• Example 19 Preparation of (S)-3-(4-(2-(5-glycyloxymethylisoxazol-3- yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid (compound 3)
• the same procedure as in Example 17 was conducted, except for using, instead of 2-(2-oxo-4-hydroxymethylpyrrolidin-l-yl)-5-bromo ⁇ yridine, 2-(5- hydroxymethylisoxazol)-5-bromopyridine as a starting material, to prepare the title compound.
• Example 20 Preparation of (S)-3-(4-(2-(2-oxo-3-glycyloxypyrrolidin-l- yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid (compound 5)
• the same procedure as in Example 17 was conducted, except for using, instead of 2-(2-oxo-4-hydroxymethylpyrrolidin-l-yl)-5-bromopyridine, 2-(2-oxo-3- hydroxypyrrolidin-l-yl)-5-bromopyridine as a starting material, to prepare the title compound.
• 1H NMR(DMSO-d 6 ) ⁇ 8.60(s,lH), 8.33(d,lH), 8.28(s,3H), 8.25(m,lH),
• Example 21 Preparation of (S)-3-(4-(2-(5-glycyloxymethyl-[l,2,41oxadiazol-3- yI)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyI acetamide trifluoroacetic acid (compound 6)
• the same procedure as in Example 17 was conducted, except for using, instead of 2-(2-oxo-4-hydroxymethylpyrrolidin-l-yl)-5-bromopyridine, 2-(5- hydroxymethyl-[l,2,4]oxadiazol-3-yl)-5-bromopyridine as a starting material, to prepare the title compound.
• Example 23 Preparation of (S)-3-(4-(4-(4-glycyloxymethylthiazol-2-yl)phenyl)- 3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid (compound 30)
• the same procedure as in Example 17 was conducted, except for using, instead of 2-(2-oxo-4-hydroxymethyl ⁇ yrrolidin-l-yl)-5-bromopyridine, 4-(4- hydroxymethyl thiazol-2-yl)-bromobenzene as a starting material, to prepare the title compound.
• Example 24 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-([l,2,41triazol-l-yl)methyl oxazolidin-2-on (compound 4) 1.
• Example 25 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyI)-5-(fl,2,3]triazol-2-yl)methyl oxazolidin-2-on(compound 8) and (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- (fl,2,3]triazol-l-yl)methyl oxazolidin-2-on(compound 9)
• the same procedure as in Example 24 was conducted, except for adding, instead of 1,2,4-triazol, 1,2,3 -triazol, to obtain compound 8 and compound 9, and then the compounds were divided by column chromatography.
• Example 27 Preparation of (R)-3-(4-(2-([l,2,41triazol-l-yl)pyridin-5-yl)-3- fluorophenyl)-5-([l,2,31triazol-l-yl)methyl oxazolidin-2-on (compound 14)
• the same procedure as in Example 24 was conducted, except for adding 1,2,3-triazol and using the compound 17 as a starting material, to obtain the title compound.
• Example 30 Preparation of (S)-3-(4-(4-(4,5-dimethyloxazol-2-yl)phenyl)-3- fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide (compound 11)
• the same procedure as in Example 1 was conducted, except for adding 4- (4,5-dimethyloxazol-2-yl)-bromobenzene and using (S)-3-(4-trimethylstannyl-3- fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide as a starting material, to obtain the title compound.
• 1H NMR(DMSO-d 6 ) ⁇ 8.24(m,lH), 7.96(m,2H), 7.62(m,4H), 7.45(dd,lH),
• Example 31 Preparation of (S)-3-(4-(2-(4,5-dimethyloxazol-2-yl)pyridin-5-yl)- 3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide (compound 15)
• the same procedure as in Example 1 was conducted, except for adding 4- (4,5-dimethyloxazol-2-yl)-5-bromopyridine and using (S)-3-(4-trimethylstannyl-3- fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide as a starting material, to obtain the title compound.
• 1H NMR(DMSO-d 6 ) ⁇ 8.81(s,lH), 8.24(t,lH), 8.07(m,2H), 7.77(t,lH), 7.62
• Example 32 Preparation of (S)-3-(4-(2-(U,2,31triazoi-2-yl)pyridin-5-yl)-3- fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide (compound 25)
• the same procedure as in Example 1 was conducted, except for adding 2- ([l,2,3]triazol-2-yl)-5-bromopyridine and using (S)-3-(4-trimethylstannyl-3- fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide as a starting material, to obtain the title compound.
• Example 33 Preparation of (S)-3-(4-(4-(4(4(S)-hvdroxymethyl-4,5- dihydrooxazol-2-yl)phenyl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide (compound 26) The same procedure as in Example 1 was conducted, except for adding 4-
• Example 34 Preparation of (S)-3-(4-(4-(4-cyanomethyl thiazol-2-yl)phenyl)-3- fluorophenyD-2-oxo-5-oxazolidinylmethyl acetamide (compound 31)
• the same procedure as in Example 1 was conducted, except for adding 4-(4- cyanomethyl thiazol-2-yl)-bromobenzene and using (S)-3-(4-trimethylstannyl-3- fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide as a starting material, to obtain the title compound.
• Example 35 Preparation of (R)-3-(4-(4-(4-(4-hydroxy methyl thiazol-2-yDphenyl)- 3-fluorophenyl)-5-(fl,2,31triazol-l-yl)methyl oxazolidin-2-on (compound 36)
• the same procedure as in Example 1 was conducted, except for adding 4-(4- hydroxymethyl thiazol-2-yl)-bromobenzene and using (R)-3-(4-trimethylstannyl-3- fluorophenyl)-5-[l,2,3]triazol-l-yl oxazolidin-2-on as a starting material, to obtain the title compound.
• Example 36 Preparation of (R)-3-(4-(4-(4-(4-glycyloxy methyl thiazol-2- yl)phenyl)"3-fluorophenyl)-5-(f 1,2,31 triazol-1 -yl)methyl oxazolidin-2-on trifluoroacetic acid (compound 37)
• the same procedure as in Example 10 was conducted, except for using (R) ⁇ 3-(4-(4-(4-hydroxymethyl thiazol-2-yl)phenyl)-3-fluorophenyl)-5-[l,2,3]triazol-l- ylmethyl oxazolidin-2-on as a starting material, to obtain the title compound.
• Example 38 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-(N,N-dimethylaminomethyl)oxazolidin-2-on (compound 40)
• compound 40 In 5ml of dimethylformamid was dissolved lOOmg of (R)-3-(4-(2-(2- methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-methansulfonyloxymethyl oxazolidin-2-on prepared in the secondary step of the Example 24.
• the solution was added with 30mg of dimethylamine hydrochloride at room temperature.
• Example 39 Preparation of (S)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-N-methylaminomethyl oxazolidin-2-on (compound 41)
• compound 41 In 7ml of dimethylformamid was dissolved 200mg of (R) ⁇ 3-(4-(2-(2- methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-methansulfonyloxymethyl oxazolidin-2-on, prepared in the primary step of the Example 24.
• the solution was added with lOOmg of methylamine hydrochloride and 240mg of potasiumcarbonate at room temperature. The solution was stirred for 30 hours at the temperature of 80 °C . The solution was added with ethyl acetate and then the organic layer, thus separated, was washed with water and brine. The residue, prepared by dehydrating, filtering and concentrating the organic layer, was purified by column chromatography to obtain the title compound 80mg. Yield 45%.
• Example 40 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-vI)-3- fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-on trifluoroacetic acid (compound 42)
• the same procedure as in Example 10 was carried out to provide the title compound using BOC-L-alanine instead of BOC-glycine.
• Example 41 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yI)-3- fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-on hydrochloride (compound 43J_ 500mg of compound 20, prepared in Example 11, was dissolved in water.
• the solution was controlled to pH 5 with the addition of sodium bicarbonate aqueous solution.
• the aqueous layer was extracted with ethyl acetate and then the organic layer was slowly added with ether solution saturating of hydrochloric acid.
• the solid prepared by the above method was filtered and concentrated in vacuo to provide the title compound 200mg. Yield 46%.
• Example 42 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-on hydrochloride (compound 44 With the exception of using compound 42, the same procedure as in Example 41 was conducted to prepare the title compound.
• Example 43 Preparation of (R)-3-(4-(2-(2-methyltetrazoI-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on hydrochloride (compound 45) With the exception of using the compound 12, the same procedure as in Example 41 was conducted to prepare the title compound.
• Example 44 Preparation of (S)-3-(4-(4-(4-(4-hydroxymethylthiazol-2-yl)phenyl)- 3-fluorophenyl)-2-oxo-5-oxazolidinylmethyI acetamide (compound 28) With the exception of using (S)-3-(4-trimethylstannyl-3-fluoro ⁇ henyl)-2- oxo-5-oxazolidinylmethyl acetamide as a starting material and 4-(4- hydroxymethylthiazol-2-yl)-bromobenzene, the same procedure as in Example 1 was conducted to prepare the title compound.
• Example 45 (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- (L- prolinyloxy)methyl oxazolidin-2-on trifluoroacetic acid (compound 46)
• BOC-L-proline instead of BOC-glycine, the same procedure as in Example 10 was conducted to prepare the title compound.
• Example 46 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-(L- prolinyloxy)methyl oxazolidin-2-on hydrochloride (compound 47) With the exception of using the compound 46, the same procedure as in Example 41 was conducted to prepare the title compound.
• Example 47 Preparation of (R)-3-(4-(2-(2-methvHl,3,41oxadiazol-5-yl)pyridin- 5-yD-3-fluorophenyI)-5-glveyloxymethyl oxazolidin-2-on hydrochloride (compound 48) With the exception of using the compound 27, the same procedure as in Example 41 was conducted to prepare the title compound. !
• Example 48 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-vI)-3- fluorophenyl)-5-(/3-alanyloxy)methyl oxazolidin-2-on trifluoroacetic acid (compound 49)
• BOC- ⁇ -alanine instead of BOC-glycine, the same procedure as in Example 10 was conducted to prepare the title compound.
• Example 49 Preparation of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-(ff-alanyloxy)methyl oxazolidin-2-on hydrochloride (compound 50) With the exception of using the compound 49, the same procedure as in Example 41 was conducted to prepare the title compound.
• Example 50 Preparation of (R)-3-(4-(2-(2-methyl-[l,3,41oxadiazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-(L-alanyIoxy)methyl oxazolidin-2-on trifluoroacetic acid(compound 51) With the exception of using the compound 16 and BOC-L-alanine, the same procedure as in Example 10 was conducted to prepare the title compound.
• Example 51 Preparation of (R)-3-(4-(2"(2-methyl-fl,3,41oxadiazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-on hydrochloride (compound 52) With the exception of using the compound 51, the same procedure as in
• Example 41 was conducted to prepare the title compound.
• 1H NMR(DMSO-d 6 ) ⁇ 8.93(s,lH), 8.61(bs,3H), 8.21(s,2H), 7.76(t,lH), 7.65(dd,lH), 7.49(dd,lH), 5.05(m,lH), 4.58(dd,lH), 4.39(dd,lH), 4.25(t,lH), 4.12(m,lH), 4.00(dd,lH), 2.62(s,3H), 1.36(d,3H)
• Example 52 Preparation of (R)-3-(4-(2-(2-methyl-[l,3,41oxadiazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-on trifluoroacetic acid (compound 53) With the exception of using the compound 16 and BOC-L-valline, the same procedure as in Example 10 was conducted to prepare the title compound.
• Example 53 Preparation of (R)-3-(4-(2-(2-methyl-fl,3,4]oxadiazoI-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-(L-vaIyloxy)methyl oxazolidin-2-on hydrochloride (compound 54) With the exception of using the compound 53, the same procedure as in Example 41 was conducted to prepare the title compound.
• Example 54 Preparation of (R)-3-(4-(2-(2-methyl-fl,3,41oxadiazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-(L-prolinyloxy)methyl oxazolidin-2-on trifluoroacetic acid (compound 55) With the exception of using the compound 16 and BOC-L-prroline, the same procedure as in Example 10 was conducted to prepare the title compound. 1H NMR(DMSO-d 6 ) ⁇ 9.20(bs,2H), 8.93(s,lH), 8.21(s,2H), 7.77(t,lH),
• Example 55 Preparation of (R)-3-(4-(2-(2-methyl-H,3,41oxadiazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-(L-prolinyloxy)metl ⁇ yl oxazolidin-2-on hydrochloride (compound 56) With the exception of using the compound 55, the same procedure as in Example 41 was conducted to prepare the title compound.
• Example 56 Preparation of (R)-3-(4-(2-(2-methyl-fl,3,4]oxadiazo ⁇ -5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-( 3-alanyloxy)methyl oxazolidin-2-on trifluoroacetic acid (compound 57) With the exception of using the compound 16 and BOC- ⁇ -allanine, the same procedure as in Example 10 was conducted to prepare the title compound.
• Example 57 Preparation of (R)-3-(4-(2-(2-methyl-f 1,3,41 oxadiazol-5-vDpyridin- 5-yl)-3-fluorophenyl)-5-( -alanyloxy)methyl oxazolidin-2-on hydrochloride (compound 58) With the exception of using the compound 57, the same procedure as in Example 41 was conducted to prepare the title compound. 1H NMR(DMSO-d 6 ) ⁇ 8.92(s,lH), 8.21(s,2H), 8.08(bs,3H), 7.76(t,lH),
• Example 58 Preparation of mono-f(R)-f3-(4-(2-(2-methyItetrazol-5-yl)pyridin- 5-yI)-3-fluorophenyl)-2-oxo-5-oxazolidinyllmethyll phosphate(compound 72) and (R)-f3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5- oxazolidinyll methyl disodiumphosphate (compound 59) 1.
• the Primary Step In 10ml of mixture solvent(tetrahydrofuran : methylenchloride 1: 1) was dissolved lg of compound 10. The solution was added with 0.6g of tetrazole and
• reaction mixture was refrigerated to -78 °C, added with 0.7g of metachloroperbenzoic acid and stirred for 2 hours. After being cooling to -78°C , the reaction mixture was added with metachloroperbenzoic acid (0.7g). When the reaction mixture was stirred for 2 hours, the temperature of the reaction mixture was raised to room temperature. The reaction mixture was then added with ethyl acetate.
• Example 59 Preparation of (R)-[3-(4-(2-(2-methyl-[l,3,41oxadiazol-5- yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyllmethyI disodiumphosphate (compound 60) Using the compound 16, the title compound was prepared in a manner similar to that of the Example 58.
• 1H NMR(D 2 0) ⁇ 8.33(s,lH), 7.65(dd,2H), 7.17(m,2H), 6.90(m,lH), 4.79 (m,lH), 4.63(s,3H), 3.94(t,lH), 3.78(m,3H)
• Example 60 Preparation of (R)-3-(4-(2-(l-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-hydro ⁇ ymethyl oxazolidin-2-on (compound 61) Using 2-(l-methyltetrazol-5-yl)-5-bromopyridine, the title compound was prepared in a manner similar to that of the Example 1.
• Example 61 Preparation of (R)-3-(4-(2-(l-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyQ-5-gIycyIoxymethyl oxazolidin-2-on trifluoroacetic acid (compound 62) Using 2-(l-methyltetrazol-5-yl)-5-bromopyridine, the title compound was prepared in a manner similar to that of the Example 10. 1H NMR(DMSO-d 6 ) ⁇ 8.95(s,lH), 8.20(s,3H), 8.19(m,2H), 7.80(t,lH),
• Example 62 Preparation of (R)-3-(4-(2-(l-methyltetrazoI-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on hydrochloride (compound 63) Using 2-(l-methyltetrazol-5-yl)-5-bromopyridine, the title compound was prepared in a manner similar to that of the Example 43.
• Example 63 Preparation of (R)-3-(4-(2-(l-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-(L-aIanyloxy)methyl oxazolidin-2-on trifluoroacetic acid (compound 64) Using 2-(l-methyltetrazol-5-yl)-5-bromopyridine, the title compound was prepared in a manner similar to that of the Example 40. 1H NMR(DMSO-d 6 ) ⁇ 8.95(s,lH), 8.43(s,3H), 8.25(m,2H), 7.77(t,lH),
• Example 64 Preparation of (R)-3-(4-(2-(l-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-on hydrochloride (compound 65) Using 2-(l-methyltetrazol-5-yl)-5-bromopyridine, the title compound was prepared in a manner similar to that of the Example 42.
• Example 65 Preparation of (R)-3-(4-(2-(l-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-(L-vaIyloxy)methyl oxazolidin-2-on trifluoroacetic acid (compound 66) Using 2-(l-methyltetrazol-5-yl)-5-bromopyridine, the title compound was prepared in a manner similar to that of the Example 11.
• Example 67 Preparation of (R)-3-(4-(2-(l-methyItetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-( ⁇ 3-alanyloxy)methyl oxazolidin-2-on trifluoroacetic acid (compound 68) Using 2-(l-methyltetrazol-5-yl)-5-bromopyridine, the title compound was prepared in a manner similar to that of the Example 48.
• Example 69 Preparation of mono-f(R)-f3-(4-(2-(l-methyltetrazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyll methyll phosphate(compound 73) and (R)-f3"(4-(2-(l-methyltetrazol-5-yl)pyridin-5-yI)-3-fluorophenyl)-2-oxo-5- oxazolidinyll methyl disodiumphosphate(compound 70) 1.
• Example 70 Preparation of (R)-3-(4-(2-(l-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5-(fl,2,31triazol-l-yl)methyl oxazolidin-2-on(compound 71) Using the compound 61, the title compound was prepared in a manner similar to that of the Example 24.
• the derivatives of the present invention had sufficient efficiency on antibacterial activity against Staphylococcus aureus(MRSA) and Enterococci(V XE) in spite of using lower concentration of the derivatives than that of the Zyvox. Accordingly, the compounds of the present invention may be useful as antibiotics.
• the solubility of the compound 42(>50 mg/mi) that is prodruged, of the derivatives was enhanced as compared with those of Zyvox(3 mg/mi) and the compound 10(10 ⁇ g/mi). Accordingly, when the derivatives of the present invention were formulated for oral administration, absorption of the derivatives may be enhanced. When the derivatives were formulated as injection, various formations of the derivatives may be obtained.
• composition of the present invention has no toxic effects
• the compounds of the present invention have excellent efficiency on antibacterial activity without any toxicity present according to Table 4.
• Example Formulation Preparation of Pharmaceutical composition 1. Preparation as powder Derivative of oxazolidinone 2g Lactose lg The above materials were mixed and then the mixture was filled into a closed pack to prepare as powder.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Obesity (AREA)
• Child & Adolescent Psychology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (27)

Applications Claiming Priority (4)

Related Child Applications (3)

Publications (1)

Family

ID=36660051

Family Applications (1)

Country Status (25)

Cited By (40)

Families Citing this family (46)

Citations (6)

Family Cites Families (54)

• 2004
  • 2004-07-27 KR KR1020040058809A patent/KR100854211B1/ko not_active Expired - Fee Related
  • 2004-12-17 EP EP04808458A patent/EP1699784B1/en not_active Expired - Lifetime
  • 2004-12-17 ES ES10183967T patent/ES2391820T3/es not_active Expired - Lifetime
  • 2004-12-17 NZ NZ547928A patent/NZ547928A/en not_active IP Right Cessation
  • 2004-12-17 PL PL04808458T patent/PL1699784T3/pl unknown
  • 2004-12-17 CA CA2549062A patent/CA2549062C/en not_active Expired - Lifetime
  • 2004-12-17 AU AU2004299413A patent/AU2004299413C1/en not_active Expired
  • 2004-12-17 US US10/596,412 patent/US7816379B2/en active Active
  • 2004-12-17 SI SI200431751T patent/SI1699784T1/sl unknown
  • 2004-12-17 CN CN201110304983.4A patent/CN102516238B/zh not_active Ceased
  • 2004-12-17 NZ NZ575842A patent/NZ575842A/en not_active IP Right Cessation
  • 2004-12-17 EP EP10183967A patent/EP2305657B1/en not_active Expired - Lifetime
  • 2004-12-17 DK DK04808458.6T patent/DK1699784T3/da active
  • 2004-12-17 CN CN201210155386.4A patent/CN102702184B/zh not_active Ceased
  • 2004-12-17 WO PCT/KR2004/003327 patent/WO2005058886A1/en active Application Filing
  • 2004-12-17 RU RU2006125761A patent/RU2414469C3/ru active Protection Beyond IP Right Term
  • 2004-12-17 BR BRPI0417800A patent/BRPI0417800B8/pt active IP Right Grant
  • 2004-12-17 CN CN2004800376122A patent/CN1894242B/zh not_active Ceased
  • 2004-12-17 JP JP2006545238A patent/JP4739229B2/ja not_active Expired - Lifetime
  • 2004-12-17 AT AT04808458T patent/ATE514686T1/de active
  • 2004-12-17 RU RU2010149618/04A patent/RU2559620C2/ru active
  • 2004-12-17 PT PT04808458T patent/PT1699784E/pt unknown
  • 2004-12-17 MX MXPA06006955A patent/MXPA06006955A/es active IP Right Grant
  • 2004-12-17 MX MX2012012028A patent/MX339597B/es unknown
  • 2004-12-17 CN CN2010105088241A patent/CN101982468B/zh not_active Ceased
• 2008
  • 2008-09-16 US US12/211,655 patent/US8420676B2/en active Active
• 2009
  • 2009-02-17 AU AU2009200606A patent/AU2009200606B2/en not_active Expired
• 2011
  • 2011-09-28 CY CY20111100939T patent/CY1112445T1/el unknown
• 2013
  • 2013-04-15 US US13/863,216 patent/US9163043B2/en not_active Expired - Lifetime
• 2014
  • 2014-08-13 US US14/459,161 patent/US20140350059A1/en not_active Abandoned
• 2015
  • 2015-09-01 NL NL300759C patent/NL300759I2/nl unknown
  • 2015-09-03 HU HUS1500046C patent/HUS1500046I1/hu unknown
  • 2015-09-17 BE BE2015C050C patent/BE2015C050I2/fr unknown
  • 2015-09-17 LU LU92834C patent/LU92834I2/xx unknown
  • 2015-09-18 CY CY2015036C patent/CY2015036I2/el unknown
  • 2015-09-22 FR FR15C0062C patent/FR15C0062I2/fr active Active
  • 2015-09-22 LT LTPA2015032C patent/LTC1699784I2/lt unknown
• 2016
  • 2016-08-30 US US15/251,049 patent/US20170049763A1/en not_active Abandoned
• 2017
  • 2017-06-07 US US15/616,021 patent/US20170333414A1/en not_active Abandoned
• 2018
  • 2018-08-03 US US16/054,538 patent/US20180344716A1/en not_active Abandoned
• 2019
  • 2019-11-12 US US16/681,206 patent/US20200078345A1/en not_active Abandoned
• 2020
  • 2020-06-08 US US16/895,816 patent/US20210121449A1/en not_active Abandoned

Patent Citations (6)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events